Skip to main content

Spikevax COVID-19 Vaccine Coverage Update

Last updated on

Beginning June 1, 2022, Medicaid will cover the brand name Spikevax COVID-19 vaccine national drug codes (NDCs) for Medicaid and the Children’s Health Insurance Program (CHIP) as a payable pharmacy benefit. Spikevax is the brand name for the Moderna COVID-19 vaccine and has its own unique NDC.

On January 31, 2022, the U.S. Food and Drug Administration (FDA) issued full approval of the Moderna COVID-19 vaccine, now marketed as Spikevax, for individuals 18 years of age or older. Spikevax has the same formulation as the emergency use authorization (EUA) Moderna COVID-19 vaccine and the same administration schedule in which the primary series of two doses is given by a health-care provider with one month between doses. The original Moderna COVID-19 vaccine is also available under the EUA. Spikevax can be used interchangeably with the EUA Moderna COVID-19 vaccine without presenting any safety or effectiveness concerns.

The following NDCs have been added to the formulary for Medicaid and CHIP as a reimbursable pharmacy benefit:

Drug Name



Spikevax COVID-19 Vaccine

0.5 mL


Spikevax COVID-19 Vaccine

0.5 mL


Email comments or questions to